U.S. Gains COVID-19 Drug Monopoly for Gilead’s 31,900% Markup
The U.S. government and Gilead have colluded in the fleecing of taxpayers by agreeing a huge 31,900% markeup for Covid-19 drug remdesivir.
Gilead Sciences
Gilead Sciences Stock Is Rallying – And the Reason Why May Sicken You
Gilead Sciences stock is rallying today. But it’s safe to say the reason why – remdesivir’s four-figure price tag – is going to sicken you.
The Stock Market Is Insane to Rally on Gilead’s Flimsy Remdesivir Study
U.S. stock markets are rallying after an inconclusive study on Gilead’s remdesivir. The flimsy trial didn’t even have a control group.
Why Your Favorite ‘Coronavirus Stock’ Just Took Wall Street on a Nasty Ride
Gilead was quick to downplay a leaked WHO document showing its coronavirus treatment failed in a Chinese trial. But the numbers don’t add up.
Dow Swings Wildly After Trial ‘Flop’ Ignites Coronavirus Drug Fears
The Dow Jones swung wildly after coronavirus drug remdesivir failed its first trial and ING reported a harrowing unemployment stat.
This Is Why the Dow Jones Soared While Its 2 Biggest Stocks Dove
The Dow Jones soared into the closing bell, even as its biggest stocks – UnitedHealth and Apple – dove back into decline. Here’s why.
Why It’s Too Early to Celebrate Gilead Sciences’ Coronavirus Therapy
Remdesivir, an antiviral drug developed by Gilead Sciences to treat Ebola, has shown anecdotal evidence of treating COVID-19.